1.
Detection of infliximab levels and anti-infliximab antibodies: a comparison of three different assays
by Vande Casteele, N.
Alimentary pharmacology & therapeutics, 2012, Vol.36 (8), p.765-771
2.
The diagnostic value of 124I-PET in patients with differentiated thyroid cancer
by Phan, Ha T. T
European journal of nuclear medicine and molecular imaging, 2008, Vol.35 (5), p.958-965
3.
Letter: detection of infliximab levels and anti-infliximab antibodies--comparison of three different assays; authors' reply
by Buurman, D. J
Alimentary pharmacology & therapeutics, 2013, Vol.37 (2), p.282-282
4.
The diagnostic value of I-124-PET in patients with differentiated thyroid cancer
by Phan, Ha T. T
European journal of nuclear medicine and molecular imaging, 2008, Vol.35 (5), p.958-965
5.
Letter: detection of infliximab levels and anti-infliximab antibodies - comparison of three different assays; authors' reply
by Buurman, D. J
Alimentary pharmacology & therapeutics, 2013, Vol.37 (2), p.282-282
6.
Detection of infliximab levels and anti-infliximab antibodies: a comparison of three different assays
by Vande Casteele, N
Alimentary pharmacology & therapeutics, 2012, Vol.36 (7), p.765
7.
Detection of infliximab levels and anti-infliximab antibodies: a comparison of three different assays
by Casteele, N. Vande
Alimentary pharmacology & therapeutics, 2012, Vol.36 (8), p.765-771
8.
Fatal intracranial haemorrhage associated with the administration of low-molecular-weight-heparin in a child
by Van Heerde, Marc
European journal of pediatrics, 2005, Vol.164 (9), p.589-590
9.
The diagnostic value of 124.sup.I-PET in patients with differentiated thyroid cancer
by Phan, Ha T. T
European journal of nuclear medicine and molecular imaging, 2008, Vol.35 (5), p.958
10.
COPD in the general population: Prevalence, incidence and survival
by Afonso, Ana S.M
Respiratory medicine, 2011, Vol.105 (12), p.1872-1884
11.
The incidence of narcolepsy in Europe: Before, during, and after the influenza A(H1N1)pdm09 pandemic and vaccination campaigns
by Wijnans, Leonoor
Vaccine, 2012, Vol.31 (8), p.1246-1254
12.
Risk of recurrent myocardial infarction with the concomitant use of clopidogrel and proton pump inhibitors
by Valkhoff, Vera
Alimentary pharmacology & therapeutics, 2011, Vol.33 (1), p.77-88
13.
The incidence of Barrett's oesophagus and oesophageal adenocarcinoma in the United Kingdom and the Netherlands is levelling off
by Masclee, Gwen
Alimentary pharmacology & therapeutics, 2014, Vol.39 (11), p.1321-1330
14.
Fatal outcomes following immunization errors as reported to the EudraVigilance: A case series
by Hoeve, Christina E
Vaccine, 2020, Vol.38 (15), p.3086-3095
15.
16.
Cyclo-oxygenase-2 inhibitors or nonselective NSAIDs plus gastroprotective agents: what to prescribe in daily clinical practice?
by Masclee, Gwen
Alimentary pharmacology & therapeutics, 2013, Vol.38 (2), p.178-189
17.
Low varicella-related consultation rate in the Netherlands in primary care data
by van Lier, Alies
Vaccine, 2014, Vol.32 (28), p.3517-3524
18.
Letter: incidence rates of Barrett's oesophagus and oesophageal adenocarcinoma in UK and the Netherlands - authors' reply
by Masclee, Gwen
Alimentary pharmacology & therapeutics, 2014, Vol.40 (4), p.404-404
19.
Prescription of nonselective NSAIDs, coxibs and gastroprotective agents in the era of rofecoxib withdrawal - a 617 400-patient study
by Valkhoff, V. E.
Alimentary pharmacology & therapeutics, 2012, Vol.36 (8), p.790-799
20.
Advance system testing: Vaccine benefit studies using multi-country electronic health data – The example of pertussis vaccination
by Tin Tin Htar, Myint
Vaccine, 2020, Vol.38, p.B31-B37
